|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02126 JW THERAP-B
Nominal 
3.600 -0.140 (-3.743%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 158,218 | -8.995% | 173,856 | 145,702 | 30,797 | 0 |
| Cost of Sales | (80,902) | -5.529% | (85,637) | (86,946) | (21,752) | -- |
| Gross Profit | 77,316 | -12.359% | 88,219 | 58,756 | 9,045 | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | 51,151 | (1,225,636) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (590,624) | -23.095% | (767,996) | (846,135) | (702,328) | (1,663,803) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (590,624) | -23.095% | (767,996) | (846,135) | (702,328) | (1,663,803) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (16,211) | -24.987% | (21,611) | (9,748) | (5,604) | (2,671) |
| Depreciation & Amortisation | 77,244 | -1.816% | 78,673 | 84,810 | 45,648 | 23,590 |
| Directors' Emoluments | 24,680 | 8.089% | 22,833 | 32,981 | 47,163 | 102,732 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -143.000 | -23.529% | -187.000 | -206.000 | -176.000 | -1,261.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.806) | -- | (0.968) | (1.309) | (1.404) | (1.979) |
| NBV per share ($) | 2.814 | -- | 4.083 | 5.728 | 6.847 | 8.842 |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -267,265 |
| %Change | 11.237% |
| EPS / (LPS) | RMB -0.640 |
| NBV Per Share (¥) | RMB 2.183 |